Skip to main content

Table 2 Baseline table of vision loss

From: Vision loss in patients with giant cell arteritis treated with tocilizumab

  All Normal vision at baseline Vision loss before baseline p value
n (%) or median (IQ range) n (%) or median (IQ range) n (%) or median (IQ range)  
Total N N = 186 N = 165 N = 21  
Female 116 (62%) 101 (61%) 15 (71%) 0.475
Age at diagnosis 71.0 (63.0; 77.0) 70.0 (63.0; 76.0) 74.0 (69.5; 82.0) 0.032
Weight [kg] 70.0 (59.0; 83.4) 71.9 (59.1; 83.3) 61.6 (54.1; 85.5) 0.178
BMI [kg/m2] 24.9 (22.0; 28.4) 25.2 (22.0; 28.4) 23.7 (21.3; 27.7) 0.237
First CRP (mg/L) 50.0 (20.0; 99.0) 54.5 (21.0; 101.3) 20.0 (3.5; 47.5) 0.002
First ESR (mm/h) 70.0 (40.0; 86.3) 70.0 (40.0; 87.5) 50.0 (34.0; 78.0) 0.197
ACR Criteria 1990 109 (59%) 94 (57%) 15 (71%) 0.245
Cranial symptoms (incl. Visual sympt.) 124 (67%) 103 (62%) 21 (100%) < 0.001
Visual symptoms 70 (38%) 49 (30%) 21 (100%) < 0.001
Permanent vision loss 21 (11%) 0 (0%) 21 (100%) < 0.001
Headache 93 (50%) 83 (50%) 10 (48%) 1.000
Jaw claudication 48 (26%) 38 (23%) 10 (48%) 0.031
Scalp tenderness 42 (23%) 36 (22%) 6 (29%) 0.579
Claudication of tongue 2 (1%) 1 (1%) 1 (5%) 0.214
Fever ≥ 38 °C 35 (19%) 35 (21%) 0 (0%) 0.015
Weight loss > 2 kg within 4 weeks 50 (27%) 42 (25%) 8 (38%) 0.295
Night sweat 33 (18%) 29 (18%) 4 (19%) 1.000
Polymyalgia rheumatica 90 (48%) 84 (51%) 6 (29%) 0.062